{"name":"3D Medicines","slug":"3d-medicines","ticker":"","exchange":"","domain":"3dmedicines.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Gemcitabine & oxaliplatin","genericName":"Gemcitabine & oxaliplatin","slug":"gemcitabine-oxaliplatin","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Envafolimab plus Gemcitabine&Cisplatin","genericName":"Envafolimab plus Gemcitabine&Cisplatin","slug":"envafolimab-plus-gemcitabine-cisplatin","indication":"Advanced solid tumors","status":"phase_2"},{"name":"KN035 plus Gemcitabine & oxaliplatin","genericName":"KN035 plus Gemcitabine & oxaliplatin","slug":"kn035-plus-gemcitabine-oxaliplatin","indication":"Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"3D229","genericName":"3D229","slug":"3d229","indication":"Other","status":"phase_1"},{"name":"Envafolimab with new manufacturing process","genericName":"Envafolimab with new manufacturing process","slug":"envafolimab-with-new-manufacturing-process","indication":"Other","status":"phase_1"},{"name":"3D189","genericName":"3D189","slug":"3d189","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"3D185","genericName":"3D185","slug":"3d185","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Gemcitabine & oxaliplatin","genericName":"Gemcitabine & oxaliplatin","slug":"gemcitabine-oxaliplatin","phase":"phase_3","mechanism":"Gemcitabine and oxaliplatin are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, with gemcitabine acting as a nucleoside analog and oxaliplatin forming platinum-DNA crosslinks.","indications":["Pancreatic cancer","Biliary tract cancer","Gastric cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"3D185","genericName":"3D185","slug":"3d185","phase":"phase_2","mechanism":"3D185 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"3D229","genericName":"3D229","slug":"3d229","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Envafolimab with new manufacturing process","genericName":"Envafolimab with new manufacturing process","slug":"envafolimab-with-new-manufacturing-process","phase":"phase_1","mechanism":"Envafolimab blocks PD-L1 to restore T-cell activity against tumor cells.","indications":[],"catalyst":""},{"name":"3D189","genericName":"3D189","slug":"3d189","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Envafolimab plus Gemcitabine&Cisplatin","genericName":"Envafolimab plus Gemcitabine&Cisplatin","slug":"envafolimab-plus-gemcitabine-cisplatin","phase":"phase_2","mechanism":"Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"KN035 plus Gemcitabine & oxaliplatin","genericName":"KN035 plus Gemcitabine & oxaliplatin","slug":"kn035-plus-gemcitabine-oxaliplatin","phase":"phase_3","mechanism":"KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy.","indications":["Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin)","Advanced biliary tract cancer (in combination with gemcitabine and oxaliplatin)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOTWoxbVpva211eWR2SzZ2WmdJeXJvMlFGUUhxSmVaTl80OENseG9yZjJwLVZ0dFpYV0twaWdhY1Z6SWR5Yi1uRkJ5LXRDZjNmd2lCYlRsenNNVV84bHdpTlJjTFRUOE5Id21yN2VOWGppVWp4MGZPbVFaT0Mwc2JrNVdxWmtzVGlGcFZGWkZpTHRnbXlpaWRqaE5ubXNuQXZZUTI4YW9RbjNOQzItb3c?oc=5","date":"2025-11-30","type":"pipeline","source":"PharmTech.com","summary":"FAQ: Everything to Know about 3D Printing in Pharma Manufacturing and Packaging - PharmTech.com","headline":"FAQ: Everything to Know about 3D Printing in Pharma Manufacturing and Packaging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdXdmWGxHMERFN25nQVIyaXZxalJQSGtvZGJzVG1JczhUczFxLUFZZ3hydktubURkdE9IeU1TT3UtUzk1MGktd2FEOFV0RFpkNlpac1lhQVBTcmhuUXZGSjFfdDAyMWh4X1RXU0h5N2c4ZTJ1OVI2TjRCOWhMenRqRVByUS02U2dMRFpidmhrLUVELWVTVF9YSWItcl82NjBMM0N0V1owZHU4ZjRiSXBmV1ROMWlsek4tVDlEb25DVQ?oc=5","date":"2025-10-08","type":"pipeline","source":"Pharmacy Practice News","summary":"3D Printing Compounded Medications SEO - Pharmacy Practice News","headline":"3D Printing Compounded Medications SEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNUUFmZEhEbVVKT29fT3hUajRjMmRUNER0Sk4xREJNMGo3TGJaXzBKVU9nUnoyb0JhdFpRVGUwQWIwVGlqYl9KNUFGeEhJSE5oemp2MjNIMW1VOHBjV1BLV28xclpiSEVmZE1GUjVJd2tGNHVUZmFjaXhPbk41c2lEMGlhaWJ2OGJlWlNNd2tYZEJUc2ZEODd0aFYwTlJ4ODg?oc=5","date":"2025-09-17","type":"pipeline","source":"Texas A&M Stories","summary":"Texas A&M researcher is revolutionizing medicine with 3D printing - Texas A&M Stories","headline":"Texas A&M researcher is revolutionizing medicine with 3D printing - Texas A&M Stories","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQMXV0bWtpY3c5Vk1XZHBrbHphdVBBZkM4TEJkVW1odnN5aGZIaHo1WWMyODZ3a2l3enNxbTNndllkQ290Ty1EZEJDeXYtQ3lUbnc0SzVuTGVkeXhvNVgxNS1YTFpBcTVMMGxiYm1rVm83Yi1oTk5rcS0yWnM4Y0pOWGZlRUV6THllaW1MZ0VuQmlsZmRDNGhGN3QySG1NUQ?oc=5","date":"2025-09-17","type":"deal","source":"MobiHealthNews","summary":"Pete Pharma, Fabrx partner to bring pharmaceutical 3D printing to the U.S. - MobiHealthNews","headline":"Pete Pharma, Fabrx partner to bring pharmaceutical 3D printing to the U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOWWZNUHZSRmp1ZlRQV3lIdmFicmpwcEVMbXdQNHBPcGxhbnhiTWhrT3h2TG12NWtCSHdKbExWTS1VenFpU192LW5jU0czdktWM20xMnpxS3VPVEJ0TGg4T0VLaUd1azNNTnlRX3ZURHlURXQ0ZDlsdTNFeHdJcW5yWWJmRHNjMUtXQUhkREZvNkVad29OTWlNS3NleFU1VFNIbVl0Yjd1bGQ0N0dRRzVCamE4UDlOeHRSNTFZV21Fc0N0Y0ZOS0tQXw?oc=5","date":"2025-08-04","type":"pipeline","source":"University College London","summary":"3D printing event hosted by the Royal Pharmaceutical Society and Academy of Pharmaceutics - University College London","headline":"3D printing event hosted by the Royal Pharmaceutical Society and Academy of Pharmaceutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNWi1sQWtPMjBwbng4ZC1yaDhoTHM3YTRGa1lrUXRrbWdrd0VQNmZTb0kyZFdqNHZScWFOU0pCSmVual9JTHYtbDlyRHMxMWpnd01uVmJuYXhZWGVxUlVqQlZDa21QZ1pKWnhBcTEwTXBSMmdxcHpmOTU0WHJIY2M4WGhtUEtRQUV2aC1QMUFxdDQtTzh0cFIyOUFIdllrbTBYbXVPWGtOTUFNZlNnaW5aZF9KcEtWWWlBS25MM2p1Z1hZZw?oc=5","date":"2025-07-29","type":"pipeline","source":"stjude.org","summary":"Personalized, palatable, precise: Transforming pediatric medication delivery - stjude.org","headline":"Personalized, palatable, precise: Transforming pediatric medication delivery","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-24","type":"pipeline","source":"3dnatives.com","summary":"CurifyLabs and the Automated Production of Personalized Medicines through 3D Printing - 3dnatives.com","headline":"CurifyLabs and the Automated Production of Personalized Medicines through 3D Printing - 3dnatives.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPdHhQNE9odkhkMEhLdHotT2ZoRm8wTzFzTHBfLUV5b2E3YXpmNEYwbkJtQzAwMWx3Y05sWkZaTEJMR1BZRTJlSXdLWHIyNU5zNE1KZXcyMzB0bjhRNGhXekQ2Vk8tckthUzRhTXNuSENFNDB0dzhibl93cjExa0VKdE9NVDZORlk5RHBoRE9tNmxBeDhIaWZEOHlsYmh4UWhGcEY0NTAzYkFtTU9ROEJHQm55UUtGQ0NDMEJVcWozUzBlTTNWdU1idHFKS19JZFBNZDJPYjBLcEJTbUlzNG0zMEd4UWszYkk?oc=5","date":"2025-07-23","type":"pipeline","source":"Hospital Pharmacy Europe","summary":"From ward manipulations to 3D printing: shaping the future of personalised medication - Hospital Pharmacy Europe","headline":"From ward manipulations to 3D printing: shaping the future of personalised medication","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNcEVrcFlBTXJmVTNRa0kwd2M4ME9pVk9JOTdiR1lSSk9JV1NRbjdXQXdyeUFnTV9DSktNa0pHWWQ0Mm1WSFBfQ3otTHZ0dFY2azdHb2k4X0FQLVpnNFFIeXp0T2NuXzB5OEZoYU9NdTJDUVJRTEJCU2JwbGI0TjBtZVNrdVRYNGM?oc=5","date":"2025-07-08","type":"pipeline","source":"TNO","summary":"3D Pharma Printing: Personalised medicine begins here - TNO","headline":"3D Pharma Printing: Personalised medicine begins here","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNd2ZiWkdHMXRkUUZuWWtCbUx6OFRIRHFGOHZaWTF5ZjAteExrVF9lSFQ0dnFkX0czWXg2Nk4wVGhud0lCd25tWEtNZm5HSkllam42VmdReFBrZjdhNlNFQ3hhX3J4ZS15ZjRrcHcxR1hTNnYwcWcxeEhSZFZudzFnaVBNS25nOG55RUhfM3ZERWozOGxFMkZTT1c4bVkwdlZMb3pLNEZXQmM3SXRhQVdCQ011VGJWNWpRQkhmMXZQRVZpR2NIVFFSNmE2Y1cwel9IXzBxS3JaNnV0YjFLZmpHdmVpaFd6dGtBUnBMYm5NcERINzZyVDgzLXdvT1lhVWxzdW53VkxXYlpTR2cxNk1oYWI5TThtT0FTYy04c2syUEhLcDBtUTB6V3RCRm9JdG9saVNWT1RZN0xNdzVxR28yUWRmWXpkWXF2?oc=5","date":"2024-01-25","type":"deal","source":"prnewswire.com","summary":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World - prnewswire.com","headline":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (En","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNelczaWhmb0RTVGVqakxyT2RLdHlMWkt4dXRtUlJLckNVNXVTREJuMW9nTlB4WHI3em82RnRjUG1RMUFPYkRRZkoyUVB4eWNpZFFzbnJUNUwydUk5dTFrZEpEQlNFb1NhRHlwT2VSZTN6UHI3WEg2cjBaZ0dJNEc4NzJaWW5JXzJOZFE?oc=5","date":"2024-01-25","type":"deal","source":"pharmaphorum","summary":"Glenmark licenses cancer drug from China’s Alphamab, 3D Med - pharmaphorum","headline":"Glenmark licenses cancer drug from China’s Alphamab, 3D Med","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdkpkaGY3MllmWGRDM3pFTjRiVHIxcTdmSXlxcUdXSEt1bXBoaGhGWGNYNmNHUk95VGpKSkM3QmNIUjRhdDBMUUFVM2E4U3hYTzI0YnJpaXhXNVRJeUhLQXh3VFdoZy1FZUN5RjF3Z2R5bGVfOWppeWJrQUxBWlFGWUhGRWhobmMtVVpueHRhU0tUNXZvTlZsYW9UaTZIcGtHd1E?oc=5","date":"2022-07-28","type":"pipeline","source":"Labiotech.eu","summary":"Five companies personalizing treatments with 3D printed drugs - Labiotech.eu","headline":"Five companies personalizing treatments with 3D printed drugs","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":2,"phase_2":2,"phase_1":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}